Syngen Biotech Co.,Ltd. (TPEX:8279)

Market Cap	3.51B
Revenue (ttm)	2.00B
Net Income (ttm)	238.77M
Shares Out	27.10M
EPS (ttm)	8.81
PE Ratio	14.70
Forward PE	n/a
Dividend	5.00 (3.92%)
Ex-Dividend Date	Jun 27, 2024

Volume	45,367
Average Volume	11,690
Open	127.50
Previous Close	127.50
Day's Range	127.00 - 129.50
52-Week Range	122.50 - 177.00
Beta	0.43
RSI	56.89
Earnings Date	Mar 7, 2025

About Syngen Biotech

Syngen Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of microbial pharmaceutical raw materials, biological pesticides, fertilizers and biochemical nutritional products, and preventive medicines in Taiwan, China, and internationally. The company offers dietary supplements; supplement contract manufacturing services in the form of sachets, liquids, tablets, cup package capsules, jellies, aluminum and glass bottles, and gummies; science-based and bio active pharmaceutical ingredient...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 247
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 8279

Financial Performance

In 2023, Syngen Biotech's revenue was 1.84 billion, a decrease of -4.84% compared to the previous year's 1.93 billion. Earnings were 274.83 million, a decrease of -14.45%.